Michael Anstead, MD

7/1/11 → 6/30/12

Project: Research project

Mpex 209 Study

Anstead, M., Danov, Z. & Kanga, J.

Mpex Pharmaceuticals

6/22/11 → 7/1/13

Project: Research project

Mpex 207 study

Anstead, M., Danov, Z. & Kanga, J.

Mpex Pharmaceuticals

5/15/11 → 2/28/13

Project: Research project

Evaluation of Pseudomonas Aeruginosa Serology for a Three-Part Study Consisting of EPIC-001 Clinical (Part 1) AZ0004 (Part 2) and EPIC-002 Observation (Part 3)

1/1/11 → 1/1/11

Project: Research project

A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetis and Pharmacodyhamics of VX-809 Alone and in Combination w/VX-770 in Subjects

Vertex Pharmaceuticals Inc

11/11/10 → 7/31/14

Project: Research project

Cystic Fibrosis Center Program

KY Cabinet for Health and Family Services

7/1/10 → 6/30/11

Project: Research project

Newborn Screening

Bay, C., Anstead, M., Hong-McAtee, I., Mabry, C. & Bricker, J.

7/1/10 → 6/30/11

Project: Research project

Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis

Danov, Z., Anstead, M., Kanga, J., Watts, T. & Tuney, D.

Bayer Corp

6/30/10 → 1/31/12

Project: Research project

Evaluation of Pseudomonas Aeruginosa Serology for a Three-Part Study Consisting of EPIC-001 Clinical (Part 1) AZ0004 (Part 2) and EPIC-002 Observation (Part 3)

Seattle Childrens Research Institute

2/1/10 → 1/31/12

Project: Research project

Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease Progression

Anstead, M., Ashe, L. & Craigmyle, L.

Gilead Sciences Inc

10/16/09 → 10/15/10

Project: Research project

A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation

Anstead, M. & Kanga, J.

Vertex Pharmaceuticals Inc

8/26/09 → 8/25/10

Project: Research project

Cystic Fibrosis Center Program

Kanga, J., Anstead, M., Danov, Z. & Hayes, D.

7/1/09 → 6/30/10

Project: Research project

Therapeutics Development Center

1/1/09 → 12/31/12

Project: Research project

Therapeutics Development Center

1/1/09 → 12/31/11

Project: Research project

Therapeutics Development Center

1/1/09 → 12/31/10

Project: Research project

Therapeutics Development Network 2014

Anstead, M., Danov, Z., Kanga, J. & Kuhn, R.

1/1/09 → 12/31/14

Project: Research project

Therapeutics Development Center

Kanga, J., Anstead, M., Danov, Z. & Kuhn, R.

1/1/09 → 12/31/13

Project: Research project

University of Kentucky Therapeutic Development Center

1/1/09 → 12/31/09

Project: Research project

Cystic Fibrosis Center Program

7/1/08 → 6/30/09

Project: Research project

Cystic Fibrosis Center Program

7/1/07 → 6/30/08

Project: Research project

Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseuddomonas aeruginosa

PPD Development Inc

4/12/07 → 9/9/09

Project: Research project

Cystic Fibrosis Research TDN Grant

12/1/06 → 12/31/08

Project: Research project

Cystic Fibrosis Research TDN Grant

12/1/06 → 11/30/07

Project: Research project

Cystic Fibrosis Center Program

7/1/06 → 6/30/07

Project: Research project

Multi-Center, Multi-National, Randomized, Placebo-Controlled Trial of Azithromycin in Participants with Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa

1/1/06 → 12/31/07

Project: Research project

Multi-Center, Multi-National, Randomized, Placebo-Controlled Trail of Azithromycin in Participants with Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa

1/1/06 → 12/31/06

Project: Research project

Therapeutics Development Center

1/1/06 → 12/31/09

Project: Research project

Multi-Center, Multi-National, Randomized, Placebo-Controlled Trial of Azithromycin in Participants with Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa

1/1/06 → 12/31/08

Project: Research project

Cystic Fibrosis Center Program

7/1/05 → 6/30/06

Project: Research project

Cystic Fibrosis Center Program

7/1/04 → 6/30/05

Project: Research project

Long Term Safety and Efficacy of Azithromycin in CF: Observational Study of AZ0001 Participants

Children's Hospital and Regional Medical

3/1/04 → 8/31/05

Project: Research project

Cystic Fibrosis Center Program

7/1/03 → 6/30/04

Project: Research project

A Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of 24 Weeks of Oral Treatment with BIIL 284 BS in Adult(75mg,150mg) and Pediatric(75mg) Cystic Fibrosis Patients

Boehringer-Ingelheim

5/18/03 → 5/31/05

Project: Research project

Cystic Fibrosis Center Program

7/1/02 → 6/30/03

Project: Research project

Cystic Fibrosis Center Program

7/1/01 → 6/30/02

Project: Research project

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Trial of Azithromycin inPatients with CF, Chronically Infected with Pseudomonas Aeruginosa

10/1/00 → 9/30/02

Project: Research project

Cystic Fibrosis Center Program